BioSpace News Archive

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences and events in September 2022.

Neurofenix, the neurological rehabilitation platform that uses sensors to improve patient outcomes, has raised $7 million in Series A funding.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed an amended and restated preliminary short form prospectus

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, filed its financial and operating results on 29 August 2022 for the quarter ended June 30, 2022.

SourceMark Medical announced that it has been awarded a group purchasing agreement for their Tourniquet Touch Pneumatic Tourniquet system with Premier, Inc., a healthcare improvement company uniting an alliance of approximately 4,400 U.S. hospitals and health systems and more than 250,000 other providers and organizations.

HighTide Therapeutics, Inc. (“HighTide”), announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

(“Hemostemix” or the “Company”) is pleased to announce the results of its Phase II Clinical Trial and the results of a new retrospective study of patients that underwent a trans-catheter, intramyocardial injection of angiogenic cell precursors (ACP-01) as a treatment for heart failure (ischemic and non-ischemic dilated cardiomyopathy).

“BioMark” or the “Company”) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies announced today its financial results and operational update for the quarter ended June 30, 2022.

(“Nextleaf” or the “Company”), a federally regulated manufacturer and distributor of cannabis extracts including vapes and oils, announced today its Q3 financial and operational results for the quarter ended June 30, 2022 (“Q3 2022").

Britannia Life Sciences Inc. (CSE: BLAB) (“Britannia” or the “Company”) is pleased to provide its unaudited financial results for the three months ended June 30, 2022.